, Tracking Stock Market Picks
Enter Symbol:
Amylin Pharmaceuticals, Inc. (AMLN) [hlAlert]

down 49.74 %

Amylin Pharmaceuticals, Inc. (AMLN) rated Sell with price target $12 by Canaccord Genuity

Posted on: Monday,  Mar 26, 2012  9:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Sell Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) on 03/26/2012, when the stock price was $15.55. Since
then, Amylin Pharmaceuticals, Inc. has gained 98.97% as of 08/06/2012's recent price of $30.94.
If you would have followed this Canaccord Genuity's recommendation on AMLN, you would have lost 49.74% of your investment in 133 days.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/26/2012 9:25 AM Sell
15.55 12.00
as of 12/31/2012
1 Week   
1 Month   
3 Months   
1 YTD down  -98.97 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy